LTRN · XBRL financial data

Lantern Pharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LTRN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	10	7,571	8,603	11,894	16,126	11,514
General and administrative	3,665	5,021	5,830	5,983	6,091	6,464
Total operating expenses	5,908	12,592	14,433	17,878	22,216	17,978
Operating income (loss)	—	(12,592)	(14,433)	(17,878)	(22,216)	(17,978)
Other income (expense)	—	161	(32)	1,151	693	421
Net income (loss)	(5,908)	(12,363)	(14,260)	(15,962)	(20,781)	(17,119)
Earnings per share, basic USD per share	—	(1.13)	(1.31)	(1.47)	(1.93)	(1.57)
Earnings per share, diluted USD per share	—	—	(1.31)	(1.47)	(1.93)	(1.57)
Weighted average shares, basic thousands of shares	—	10,905	10,851	10,842	10,762	10,898
Weighted average shares, diluted thousands of shares	—	—	10,851	10,842	10,762	10,898

Fiscal years (LTRN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	19,229	51,524	37,202	21,938	7,511	4,423
Marketable securities	—	19,201	17,994	19,365	16,502	5,696
Prepaid and other current assets	1,008	1,991	2,985	2,039	1,235	684
Total current assets	20,237	72,716	58,723	43,341	25,248	10,803
Property and equipment, net	22	30	48	52	47	32
Right-of-use asset	—	186	48	228	240	76
Total assets	20,360	73,950	58,836	43,648	25,572	11,036
Total current liabilities	552	2,326	2,798	2,678	4,331	4,502
Lease liability, non-current	—	53	—	61	53	—
Total liabilities	661	2,379	2,798	2,740	4,384	4,502
Accumulated deficit	(12,660)	(25,023)	(39,283)	(55,244)	(76,026)	(93,145)
Total stockholders' equity	19,699	71,571	56,038	40,908	21,188	6,534
Total liabilities and equity	20,360	73,950	58,836	43,648	25,572	11,036
Common shares outstanding (cover page) thousands of shares	11,170	10,780	10,857	10,741	10,785	11,255

Fiscal years (LTRN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(5,908)	(12,363)	(14,260)	(15,962)	(20,781)	(17,119)
Stock-based compensation	—	962	1,188	1,068	652	651
Depreciation and amortization	3	7	10	15	—	—
Net cash from operating activities	(5,652)	(10,592)	(12,767)	(14,347)	(17,813)	(15,677)
Purchases of property and equipment	—	15	28	19	13	2
Net cash from investing activities	(16)	(19,531)	179	(930)	3,369	11,057
Proceeds from issuing common stock	—	69,000	—	—	—	1,625
Share repurchases	—	940	2,482	500	—	—
Net cash from financing activities	23,665	63,416	(2,182)	(500)	67	1,498
Net change in cash	—	33,295	(14,781)	(15,805)	(14,427)	(3,088)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lantern Pharma	6,660	not reported	(2,941)*	12.8M	2.5 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66,229	not reported	(7,445)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
Grace Therapeutics	13,756	not reported	(3,221)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Annovis Bio	18,729	0*	(21,914)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	32	not reported	(244)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Karyopharm Therapeutics	54,980	33,432	(24,931)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.